{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:03:50Z","timestamp":1788581030741,"version":"build-2803163510"},"reference-count":26,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770235"],"award-info":[{"award-number":["81770235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National 13th Five-Year Key R&D Project","award":["2016YFC1301300"],"award-info":[{"award-number":["2016YFC1301300"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>A personalized antiplatelet therapy guided by a novel platelet function testing (PFT), PL-12, is considered an optimized treatment strategy in stable coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI). However, the safety and efficacy of any dual-antiplatelet therapy (DAPT) strategy may differ in relation to diabetes status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to compare the outcomes of PFT-guided personalized DAPT in stable CAD patients with and without diabetes mellitus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The PATH-PCI trial randomly assigned 2285 stable CAD patients to either personalized antiplatelet therapy or standard antiplatelet treatment. We investigated the association and interaction of diabetes on clinical outcomes across 2 treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We did not find a significant difference between the personalized group and the standard group in net adverse clinical events in either diabetes patients (10.3% vs 13.4%, P\u2005=\u2005.224) or in the nondiabetic group (3.1% vs 5.0%, P\u2005=\u2005.064). In diabetes patients (n\u2005=\u2005646, 28.3%), the overall ischemic event rates were significantly low (6.8% vs 11.3%, HR\u2005=\u20050.586, 95% CI, 0.344-0.999, P\u2005=\u2005.049) and the bleeding event rates did not differ between the 2 groups (3.5% vs 3.3%, HR\u2005=\u20051.066, 95% CI, 0.462-2.458, P\u2005=\u2005.882). Similarly, in nondiabetic patients, the overall ischemic event rates were significantly low (1.8% vs 4.2%, HR\u2005=\u20050.428, 95% CI, 0.233-0.758, P\u2005=\u2005.006) and the bleeding event rates did not differ between the 2 groups (1.6% vs 0.9%, HR\u2005=\u20051.802, 95% CI: 0.719-4.516, P\u2005=\u2005.209).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present study suggests that personalized antiplatelet therapy according to PFT can reduce ischemic events but not increase bleedings in stable CAD patients with or without diabetes who have undergone PCI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab612","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T13:20:48Z","timestamp":1629379248000},"page":"e214-e223","source":"Crossref","is-referenced-by-count":14,"title":["Diabetes and Outcomes Following Personalized Antiplatelet Therapy in Coronary Artery Disease Patients Who Have Undergone PCI"],"prefix":"10.1210","volume":"107","author":[{"given":"Ying-Ying","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou, 450002, P. R. China"},{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Geng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Tong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-2213","authenticated-orcid":false,"given":"Jin-Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Key Laboratory of Cardiac Injury and Repair of Henan Province, Zhengzhou, 450002, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-4626","authenticated-orcid":false,"given":"Xiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054,P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"issue":"10085","key":"2021121823150234800_CIT0001","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet."},{"issue":"12","key":"2021121823150234800_CIT0002","doi-asserted-by":"crossref","first-page":"e0208746","DOI":"10.1371\/journal.pone.0208746","article-title":"Impact of diabetes mellitus in patients undergoing contemporary percutaneous coronary intervention: results from a Korean nationwide study","volume":"13","author":"Yang","year":"2018","journal-title":"PLoS One."},{"issue":"12","key":"2021121823150234800_CIT0003","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2018.02.034","article-title":"Outcomes in patients with diabetes mellitus according to insulin treatment after percutaneous coronary intervention in the second-generation drug-eluting stent era","volume":"121","author":"Pi","year":"2018","journal-title":"Am J Cardiol."},{"issue":"2","key":"2021121823150234800_CIT0004","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1161\/CIRCINTERVENTIONS.115.003255","article-title":"Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients","volume":"9","author":"Koskinas","year":"2016","journal-title":"Circ Cardiovasc Interv."},{"issue":"15","key":"2021121823150234800_CIT0005","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMe1616575","article-title":"Increase in the incidence of diabetes and its implications","volume":"376","author":"Ingelfinger","year":"2017","journal-title":"N Engl J Med."},{"key":"2021121823150234800_CIT0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis."},{"issue":"1","key":"2021121823150234800_CIT0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12933-018-0669-0","article-title":"Impact of diabetes and early revascularization on the need for late and repeat procedures","volume":"17","author":"Orbach","year":"2018","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"2021121823150234800_CIT0008","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10557-020-07030-9","article-title":"Benefit-risk profile of DAPT continuation beyond 1 year after PCI in patients with high thrombotic risk features as endorsed by 2018 ESC\/EACTS myocardial revascularization guideline","volume":"34","author":"Wang","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"issue":"8","key":"2021121823150234800_CIT0009","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/bcp.14317","article-title":"Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis","volume":"86","author":"Yoon","year":"2020","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"2021121823150234800_CIT0010","doi-asserted-by":"crossref","first-page":"104877","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104877","article-title":"High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: systematic review and meta-analysis","volume":"29","author":"Alakbarzade","year":"2020","journal-title":"J Stroke Cerebrovasc Dis."},{"issue":"4","key":"2021121823150234800_CIT0011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ehjcvp\/pvz059","article-title":"Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial","volume":"6","author":"Zheng","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"18","key":"2021121823150234800_CIT0012","doi-asserted-by":"crossref","first-page":"2265-2271","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure: on behalf of the third universal definition of myocardial infarction global task force: Heart Failure Section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur Heart J."},{"issue":"20","key":"2021121823150234800_CIT0013","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jacc.2014.01.064","article-title":"Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials","volume":"63","author":"Kedhi","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"42","key":"2021121823150234800_CIT0014","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1093\/eurheartj\/ehx512","article-title":"Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study","volume":"38","author":"Escaned","year":"2017","journal-title":"Eur Heart J."},{"issue":"5","key":"2021121823150234800_CIT0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/cdt.2018.05.09","article-title":"Diabetes and antiplatelet therapy: from bench to bedside","volume":"8","author":"Rivas Rios","year":"2018","journal-title":"Cardiovasc Diagn Ther."},{"issue":"6","key":"2021121823150234800_CIT0016","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.4244\/EIJ-D-18-01077","article-title":"Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial","volume":"15","author":"Hein","year":"2019","journal-title":"EuroIntervention."},{"key":"2021121823150234800_CIT0017","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1160\/THS10-11-0739","article-title":"Inflammation and thrombosis in diabetes","volume":"105","author":"Hess","year":"2011","journal-title":"Thromb Haemost."},{"issue":"10204","key":"2021121823150234800_CIT0018","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"2021121823150234800_CIT0019","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1536\/ihj.19-654","article-title":"Comparison of durable-polymer- and biodegradable-polymer-based newer-generation drug-eluting stents in patients with acute myocardial infarction and prediabetes after successful percutaneous coronary intervention","volume":"61","author":"Kim","year":"2020","journal-title":"Int Heart J."},{"issue":"19","key":"2021121823150234800_CIT0020","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"2021121823150234800_CIT0021","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2021121823150234800_CIT0022","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121823150234800_CIT0023","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J."},{"issue":"25","key":"2021121823150234800_CIT0024","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation."},{"issue":"10","key":"2021121823150234800_CIT0025","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation."},{"issue":"8","key":"2021121823150234800_CIT0026","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1055\/s-0040-1713375","article-title":"Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes","volume":"120","author":"Liu","year":"2020","journal-title":"Thromb Haemost."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab612\/40494261\/dgab612.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e214\/41819298\/dgab612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e214\/41819298\/dgab612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:17:07Z","timestamp":1639869427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/e214\/6354863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,19]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab612","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,19]]}}}